Two more children from Madhya Pradesh's Chhindwara who were undergoing treatment for kidney failure after drinking a contaminated cough syrup have died, taking the number of such deaths in the district to 16, an official said on Tuesday.
"Today, the death of another girl was reported. So far, 16 children have died in the district," said Chhindwara Additional Collector Dhirendra Singh.
Earlier, the state government had confirmed the deaths of 14 children from Chhindwara who had allegedly consumed the cough syrup Coldrif, samples of which were found to have toxic contents.
Jayusha Yaduvanshi (2), a resident of Junnardeo in the district, died on Tuesday at a government hospital in Nagpur.
Another six children from Chhindwara are undergoing treatment at various hospitals in Nagpur, and the condition of five of them remains critical, the additional collector said.
Two-and-half-year-old Dhani Deharia, a resident of Bhariyadhana village in Tamia block, had died on Monday while undergoing treatment at the Nagpur Medical College hospital.
Her family members claimed that her health deteriorated after consuming the cold syrup prescribed by the doctor, and her kidneys failed.
A state government official in Bhopal had earlier stated that nine children from Madhya Pradesh were undergoing treatment at various hospitals in Nagpur, seven of them from Chhindwara and two from Betul.
Before the deaths of Jayusha Yaduvanshi and Dhani Daharia, the state government had confirmed the deaths of 14 children in Chhindwara.
On Monday, the state government suspended two drug inspectors and a deputy director of the Food and Drug Administration (FDA) and transferred the state's drug controller amid an investigation.
Chhindwara-based Dr Praveen Soni was arrested for alleged negligence, while a case has been filed against the company that manufactured the Coldrif cough syrup.
The Madhya Pradesh Police has formed a Special Investigation Team (SIT) to investigate the deaths and filed a case against the Tamil Nadu-based manufacturer of Coldrif.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)